Which Add-On Works Better: Empagliflozin or Sitagliptin?
A double-blind RCT finds empagliflozin gives broader cardiometabolic benefit than sitagliptin or metformin as add-on therapy in type 2 diabetes. PICO summary and commentary.
Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
Can Gum Treatment Improve Oral Health in Older Adults with Type 2 Diabetes?
An RCT finds a periodontal health programme improves oral hygiene and knowledge in older diabetic patients, but not oral-health quality of life. PICO summary and commentary.
What Affects Gum Treatment Success in Diabetes?
A machine-learning analysis finds lower baseline periodontal severity and HbA1c predict better response to gum therapy in diabetes (random forest AUC 0.83). PICO summary and commentary.
Intensive Blood Pressure Control in Diabetes With Prior Stroke: An ACCORD-BP Post-Hoc Analysis
A post-hoc analysis of 307 ACCORD-BP participants with type 2 diabetes and prior stroke links intensive systolic blood pressure control to fewer cardiovascular events. PICO summary and expert commentary.
Can Galician Olive Oil Help Control Blood Sugar?
A 24-week trial finds high-phenolic olive oil reduces insulin resistance in type 2 diabetes, but without changing lipids or blood pressure. PICO summary and commentary.
Does Slower Semaglutide Titration Improve Tolerability and Adherence?
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
Empagliflozin Lowers Norepinephrine Turnover Despite Raising Hepatic Glucose Production
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.
